The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance. Treatment with 1-hydroxylated vitamin D analogues is useful.

Original languageEnglish (US)
JournalEndocrinology and Metabolism Clinics of North America
DOIs
StateAccepted/In press - 2017

Fingerprint

Hyperparathyroidism
Chronic Renal Insufficiency
Vitamin D
Chronic Kidney Failure
Chronic Kidney Disease-Mineral and Bone Disorder
Calcium
Vascular Calcification
Osteomalacia
Bone Diseases
Intestinal Absorption
Minerals
Phosphates
Bone and Bones
1,25-dihydroxyvitamin D

Keywords

  • Chronic kidney disease
  • End-stage renal disease
  • Vitamin D analogues

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{3a4195b951f24ae28cfd97154be05c37,
title = "The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease",
abstract = "Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance. Treatment with 1-hydroxylated vitamin D analogues is useful.",
keywords = "Chronic kidney disease, End-stage renal disease, Vitamin D analogues",
author = "Ladan Zand and Rajiv Kumar",
year = "2017",
doi = "10.1016/j.ecl.2017.07.008",
language = "English (US)",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease

AU - Zand, Ladan

AU - Kumar, Rajiv

PY - 2017

Y1 - 2017

N2 - Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance. Treatment with 1-hydroxylated vitamin D analogues is useful.

AB - Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance. Treatment with 1-hydroxylated vitamin D analogues is useful.

KW - Chronic kidney disease

KW - End-stage renal disease

KW - Vitamin D analogues

UR - http://www.scopus.com/inward/record.url?scp=85030457686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030457686&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2017.07.008

DO - 10.1016/j.ecl.2017.07.008

M3 - Article

C2 - 29080646

AN - SCOPUS:85030457686

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

ER -